Nothing Special   »   [go: up one dir, main page]

DE69624116D1 - Verfahren zur behandlung von allergischem asthma - Google Patents

Verfahren zur behandlung von allergischem asthma

Info

Publication number
DE69624116D1
DE69624116D1 DE69624116T DE69624116T DE69624116D1 DE 69624116 D1 DE69624116 D1 DE 69624116D1 DE 69624116 T DE69624116 T DE 69624116T DE 69624116 T DE69624116 T DE 69624116T DE 69624116 D1 DE69624116 D1 DE 69624116D1
Authority
DE
Germany
Prior art keywords
allergic asthma
treating allergic
treating
asthma
allergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69624116T
Other languages
English (en)
Other versions
DE69624116T3 (de
DE69624116T2 (de
Inventor
B Fick
M Jardieu
B Schoenhoff
J Shire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24021032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69624116(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE69624116D1 publication Critical patent/DE69624116D1/de
Application granted granted Critical
Publication of DE69624116T2 publication Critical patent/DE69624116T2/de
Publication of DE69624116T3 publication Critical patent/DE69624116T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69624116T 1995-07-27 1996-07-24 Verfahren zur behandlung von allergischem asthma Expired - Lifetime DE69624116T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50801495A 1995-07-27 1995-07-27
US508014 1995-07-27
PCT/US1996/012275 WO1997004807A1 (en) 1995-07-27 1996-07-24 Methods for treatment of allergic asthma

Publications (3)

Publication Number Publication Date
DE69624116D1 true DE69624116D1 (de) 2002-11-07
DE69624116T2 DE69624116T2 (de) 2003-06-18
DE69624116T3 DE69624116T3 (de) 2009-07-09

Family

ID=24021032

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69624116T Expired - Lifetime DE69624116T3 (de) 1995-07-27 1996-07-24 Verfahren zur behandlung von allergischem asthma

Country Status (16)

Country Link
EP (1) EP0841946B2 (de)
JP (1) JP4153560B2 (de)
CN (2) CN101172100A (de)
AR (1) AR003468A1 (de)
AT (1) ATE225185T1 (de)
AU (1) AU715338B2 (de)
CA (1) CA2226624C (de)
DE (1) DE69624116T3 (de)
DK (1) DK0841946T4 (de)
ES (1) ES2186796T5 (de)
IL (1) IL122733A (de)
MX (1) MX9800760A (de)
PT (1) PT841946E (de)
RU (1) RU2229288C2 (de)
WO (1) WO1997004807A1 (de)
ZA (2) ZA966075B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
WO1999045777A1 (en) * 1998-03-10 1999-09-16 The Children's Hospital Of Philadelphia Compositions and methods for treatment of asthma
US6299875B1 (en) * 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
SI1324776T2 (en) * 2000-10-12 2018-06-29 Genentech, Inc. Concentrated protein formulations with reduced viscosity
BRPI0316092B8 (pt) 2002-11-08 2021-05-25 Ablynx Nv anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos
MXPA05004955A (es) 2002-11-08 2005-11-17 Ablynx Nv Anticuerpos de region unica dirigidos contra el factor-alfa de necrosis de tumor y usos de estos.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DE202006020194U1 (de) * 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
US20100311604A1 (en) * 2007-01-29 2010-12-09 Valtion Teknillinen Tutkimuskeskus Method for producing novel ige based reagents
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
EP2052736A1 (de) * 2007-10-26 2009-04-29 Nycomed Danmark ApS Parathyroidhormon-Formulierungen und ihre Verwendungen
CN105126099A (zh) * 2007-12-21 2015-12-09 弗·哈夫曼-拉罗切有限公司 抗体制剂
CN101903030A (zh) * 2007-12-21 2010-12-01 灵感生物制药学有限公司 含海藻糖的稳定化因子ix制剂
AR073997A1 (es) * 2008-10-29 2010-12-15 Wyeth Corp Formulaciones de moleculas de union a antigeno de dominio unico. metodo. kit
JP6113404B2 (ja) 2008-10-29 2017-04-12 アブリンクス エン．ヴェー． 単一ドメイン抗原結合分子の精製方法
HUE038405T2 (hu) 2009-12-15 2018-10-29 Ascendis Pharma Endocrinology Div A/S Átmenetileg polimer hordozóhoz kapcsolt száraz növekedési hormon készítmény
EP4450523A2 (de) 2010-04-02 2024-10-23 Amunix Pharmaceuticals, Inc. Bindungsfusionsproteine, bindungsfusionsprotein-arzneimittelkonjugate, xten-arzneimittelkonjugate sowie verfahren zur herstellung und verwendung davon
CN102533704A (zh) * 2010-12-30 2012-07-04 上海雅心生物技术有限公司 即配即用型的胰蛋白酶制剂
PL2691112T3 (pl) * 2011-03-31 2018-09-28 Merck Sharp & Dohme Corp. Stabilne preparaty przeciwciał przeciw ludzkiemu receptorowi programowanej śmierci pd-1 i terapie powiązane
US20140302021A1 (en) * 2011-10-25 2014-10-09 Onclave Therapeutics Limited Antibody formulations and methods
BR112016006455A2 (pt) * 2013-09-27 2017-08-01 Hanmi Pharm Ind Co Ltd ?formulação de conjugado de hormônio de crescimento humano de ação prolongada?
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
EP3653227B9 (de) 2014-11-18 2023-03-08 Ascendis Pharma Endocrinology Division A/S Neuartige polymere hgh-prodrugs
WO2016079302A1 (en) 2014-11-21 2016-05-26 Ascendis Pharma Growth Disorders Division A/S Long-acting growth hormone dosage forms
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
UA125971C2 (uk) 2017-07-25 2022-07-20 Джянгсу Хенгруй Медісін Ко., Лтд. Фармацевтична композиція, яка містить протеїновий комплекс il-15, та її застосування
CR20200394A (es) * 2018-02-09 2020-11-05 Genentech Inc Métodos terapéuticos y diagnósticos para enfermedades inflrmatorias mediadas por mostocitos
CN110732023B (zh) * 2018-07-18 2023-06-16 江苏恒瑞医药股份有限公司 一种her2抗体药物组合物及其用途
BR112023000400A2 (pt) 2020-07-10 2023-03-21 Shanghai Jemincare Pharmaceutical Co Ltd Anticorpo anti-ige engenheirado e aplicação do mesmo
TW202409078A (zh) * 2022-07-18 2024-03-01 中國大陸商蘇州創勝醫藥集團有限公司 穩定之包含抗gremlin1抗體的藥物製劑

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
AU616916B2 (en) * 1987-11-20 1991-11-14 Kissei Pharmaceutical Co. Ltd. 4h-quinolizin-4-one compounds exhibiting therapeutic activities
DE3853636T3 (de) * 1987-12-31 1999-04-08 Tanox Biosystems, Inc., Houston, Tex. Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden.
AU3923293A (en) * 1992-03-20 1993-10-21 Immunet Human monoclonal antibodies and methods for human monoclonal antibody production
JPH07118168A (ja) * 1993-10-19 1995-05-09 Tomoyasu Ra ＩｇＥ産生抑制剤
DE69333484T2 (de) * 1992-09-24 2005-03-24 Novartis Ag Umgestaltete monoklonale Antikörper gegen ein Immunglobulinisotyp
DE4344824C1 (de) * 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung

Also Published As

Publication number Publication date
CN101172099B (zh) 2012-02-15
ES2186796T3 (es) 2003-05-16
EP0841946B1 (de) 2002-10-02
MX9800760A (es) 1998-04-30
ZA966075B (en) 1998-01-19
AU6638196A (en) 1997-02-26
IL122733A (en) 2001-09-13
DE69624116T3 (de) 2009-07-09
DK0841946T3 (da) 2003-02-10
CN101172099A (zh) 2008-05-07
JPH11510172A (ja) 1999-09-07
DK0841946T4 (da) 2009-02-16
ZA966240B (en) 1998-01-23
CA2226624C (en) 2013-07-16
AR003468A1 (es) 1998-08-05
JP4153560B2 (ja) 2008-09-24
AU715338B2 (en) 2000-01-20
RU2229288C2 (ru) 2004-05-27
EP0841946A1 (de) 1998-05-20
IL122733A0 (en) 1998-08-16
ES2186796T5 (es) 2009-04-01
WO1997004807A1 (en) 1997-02-13
CA2226624A1 (en) 1997-02-13
ATE225185T1 (de) 2002-10-15
CN101172100A (zh) 2008-05-07
DE69624116T2 (de) 2003-06-18
EP0841946B2 (de) 2008-10-15
PT841946E (pt) 2003-02-28

Similar Documents

Publication Publication Date Title
DE69624116D1 (de) Verfahren zur behandlung von allergischem asthma
DE69603838D1 (de) Verfahren zur behandlung von gasen
ATE230606T1 (de) Verfahren zur vorbeugung und behandlung von allergien
DE69701714D1 (de) Verfahren zur behandlung von glassubstraten
DE69425372D1 (de) Verfahren zur behandlung endo-ostealer materialien
DE69331469D1 (de) Verfahren zur behandlung von abfällen
DE69726289D1 (de) Verfahren und zusammensetzung zur behandlung von substraten bezüglich benetzbarkeit
DE69218202D1 (de) Verfahren zur behandlung von fluoroaluminosilikatgläsern
DE69529768D1 (de) Verfahren und herstellung zur hydroverwirrung von vliesstoffen
DE69426970D1 (de) Verfahren zur Behandlung einer Ölquelle
DE59504072D1 (de) Verfahren zur herstellung von esterquats
DE69925266D1 (de) Verfahren und gerät zur behandlung von herzarhythmie
DE69507500D1 (de) Verfahren zur behandlung von kunststoffgiessformen
DE69918306D1 (de) Verfahren und vorrichtung zur behandlung von arrythmien
DE59810532D1 (de) Verfahren zur behandlung von cellulosischen formkörpern
DE69417018D1 (de) Verfahren zur behandlung von teilchenmaterial
DE69624625D1 (de) Verfahren und Vorrichtung zur Behandlung von Organohalogenkomponenten
DE69613446D1 (de) Verfahren zur Behandlung von wässerigem Strom
DE69526796D1 (de) Verfahren zur inhibierung von pflanzenkrankheiten
ATE239457T1 (de) Verfahren zur prophylaktischen behandlung von mastitis
ATE191453T1 (de) Verfahren zur herstellung von aminoethylethanolamin und/oder hydroxyethylpiperazin
DE69518824D1 (de) Verfahren zur behandlung von bremsscheiben
ATE232919T1 (de) Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür
ATE371453T1 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
DE69810449D1 (de) Verfahren zur behandlung von keimblättrigen pflanzen

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings